Asenapine's Effects on Depression in Bipolar I Disorder
Author Information
Author(s): Szegedi Armin, Zhao Jun, van Willigenburg Arjen, Nations Kari R, Mackle Mary, Panagides John
Primary Institution: Merck Research Laboratories
Hypothesis
Asenapine will reduce depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes.
Conclusion
Asenapine significantly reduced depressive symptoms in bipolar I disorder patients with acute manic or mixed episodes, while olanzapine's effects were less consistent.
Supporting Evidence
- Asenapine showed greater reductions in MADRS total scores compared to placebo at days 7 and 21.
- Remission rates for MADRS total scores ≤12 were significantly higher with asenapine than placebo.
- Changes in CGI-BP-D scores were significantly greater with asenapine compared to placebo.
Takeaway
Asenapine helps people with bipolar disorder feel less sad when they are having a tough time with their mood.
Methodology
The study analyzed data from two 3-week trials where patients were given asenapine, placebo, or olanzapine and assessed for changes in depressive symptoms.
Potential Biases
Potential bias due to the exploratory nature of the post hoc analysis.
Limitations
The analysis was post hoc and based on a subset of patients, which may not represent the broader population.
Participant Demographics
Patients were adults with bipolar I disorder experiencing manic or mixed episodes, with a mean age around 39 years.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website